Profile data is unavailable for this security.
About the company
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. Its products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It also develops hemodynamic and noninvasive brain and tissue oxygenation monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The Edwards SAPIEN family of valves, including the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. It conducts operations worldwide and is managed in various geographical regions, including the United States, Europe, Japan, and Rest of World. It sells products that are used to treat advanced cardiovascular disease in all regions.
- Revenue in USD (TTM)6.14bn
- Net income in USD1.41bn
- Incorporated1999
- Employees19.80k
- LocationEdwards Lifesciences CorpOne Edwards WayIRVINE 92614United StatesUSA
- Phone+1 (949) 250-2500
- Fax+1 (302) 655-5049
- Websitehttps://www.edwards.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| West Pharmaceutical Services Inc. | 2.93bn | 568.70m | 26.59bn | 10.60k | 48.12 | 9.94 | 38.33 | 9.08 | 7.58 | 7.58 | 39.09 | 36.72 | 0.7995 | 4.20 | 5.65 | 276,283.00 | 15.08 | 15.61 | 17.99 | 18.65 | 37.15 | 38.06 | 18.86 | 18.47 | 1.95 | -- | 0.0714 | 10.69 | 2.18 | 11.43 | 2.28 | 23.76 | 28.16 | 6.20 |
| Resmed Inc | 4.58bn | 958.38m | 31.88bn | 10.14k | 33.40 | 6.88 | 28.00 | 6.95 | 6.50 | 6.50 | 31.07 | 31.52 | 0.6777 | 2.20 | 5.99 | 452,086.70 | 14.17 | 13.59 | 15.98 | 15.89 | 55.78 | 56.98 | 20.91 | 19.22 | 1.97 | 25.88 | 0.1786 | 36.66 | 18.02 | 12.53 | 15.15 | 14.63 | 13.40 | 4.68 |
| GE HealthCare Technologies Inc | 19.50bn | 1.57bn | 36.26bn | 51.00k | 23.14 | 4.89 | 16.31 | 1.86 | 3.43 | 3.43 | 42.54 | 16.24 | 0.6013 | 5.45 | 4.51 | 382,254.90 | 5.01 | -- | 6.86 | -- | 40.69 | -- | 8.33 | -- | 0.8335 | 5.27 | 0.5491 | -- | 6.60 | -- | -26.82 | -- | -- | -- |
| DexCom Inc | 3.80bn | 639.30m | 51.05bn | 9.60k | 84.61 | 22.63 | 61.05 | 13.43 | 1.52 | 1.52 | 8.99 | 5.67 | 0.6337 | 2.93 | 4.71 | 396,020.80 | 10.66 | 8.30 | 14.97 | 10.50 | 63.25 | 65.90 | 16.82 | 14.14 | 2.53 | -- | 0.526 | 0.00 | 24.49 | 28.56 | 58.70 | -- | 28.66 | -- |
| Edwards Lifesciences Corp | 6.14bn | 1.41bn | 51.37bn | 19.80k | 36.64 | 7.21 | 32.97 | 8.36 | 2.33 | 2.33 | 10.11 | 11.82 | 0.6682 | 1.35 | 8.00 | 310,272.70 | 15.34 | 16.63 | 17.58 | 19.12 | 76.63 | 76.71 | 22.95 | 24.84 | 2.67 | -- | 0.0767 | 0.00 | 11.56 | 10.03 | -7.85 | 13.70 | 1.96 | -- |
| Becton Dickinson and Co | 19.72bn | 1.36bn | 67.80bn | 73.00k | 49.95 | 2.66 | 18.55 | 3.44 | 4.70 | 4.54 | 67.74 | 88.32 | 0.3633 | 3.37 | 7.93 | 270,082.20 | 2.54 | 2.37 | 2.94 | 2.70 | 41.25 | 45.78 | 6.99 | 6.95 | 0.9705 | 6.91 | 0.4126 | 81.23 | 2.66 | 3.92 | -4.85 | 12.97 | -0.4737 | 3.94 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 49.75m | 8.27% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 32.74m | 5.44% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 26.96m | 4.48% |
| AllianceBernstein LPas of 31 Dec 2023 | 19.09m | 3.18% |
| Wellington Management Co. LLPas of 31 Dec 2023 | 16.83m | 2.80% |
| Brown Advisory LLCas of 31 Mar 2024 | 13.98m | 2.33% |
| Walter Scott & Partners Ltd.as of 31 Mar 2024 | 13.03m | 2.17% |
| Geode Capital Management LLCas of 31 Dec 2023 | 12.87m | 2.14% |
| Capital Research & Management Co. (International Investors)as of 31 Dec 2023 | 9.04m | 1.50% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 8.51m | 1.42% |
